RxDoctor Payments Data

Zachary Watson, NP

Family · Mansfield, OHNPI 1275810608

Payments from drug & device makers

$333in general payments, 2019–2025

Across 19 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$131
  • Dexcom, Inc.$39
  • Medtronic$36
  • Amryt Pharma Holdings Ltd$36
  • Radius Health, Inc.$32
  • Lilly USA, LLC$30
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$333100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$333 in reported general payments places this provider in the 50th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$63,623
Medicare patients
374
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide288$372,620
TrulicityDulaglutide178$202,798
JardianceEmpagliflozin194$184,565
Humulin R U-500 KwikpenInsulin Regular, Human94$145,487
MounjaroTirzepatide85$129,438
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7146$119,536
Fiasp FlextouchInsulin Aspart (Niacinamide)55$68,163
FarxigaDapagliflozin Propanediol60$51,137
Humalog Kwikpen U-100Insulin Lispro121$49,853
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog70$41,603
JanuviaSitagliptin Phosphate35$40,887
RybelsusSemaglutide25$40,843
Lantus SolostarInsulin Glargine,hum.Rec.Anlog271$37,890
Insulin Lispro Kwikpen U-100Insulin Lispro138$36,459
Humalog Kwikpen U-200Insulin Lispro13$32,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp$131$432,898330 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$30$346,231382 claims
Radius Health, Inc.Tymlos$32$29,33711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,812 family providers in Ohio.

Other family in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →